Can an inhaled protein save lungs in Alpha-1? new trial aims to find out
NCT ID NCT04204252
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether inhaling alpha-1 antitrypsin (AAT) daily can slow lung function loss in people with Alpha-1 deficiency and moderate-to-severe lung disease. 220 adults will receive either the drug or a placebo for two years, then all will receive the drug for two more years. Researchers will measure lung function, lung density on CT scans, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Alpha-1 antitrypsin (AAT) for inhalation
What this could lead to
If it works, this could provide a new inhaled treatment to slow lung function decline in people with Alpha-1 antitrypsin deficiency.
What could go wrong
This is a Phase 3 trial, but results are not yet known. The drug may not slow lung decline better than placebo, and daily inhalation requires commitment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beaumont Hospital
RECRUITINGDublin, D09 YD60, Ireland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Canisius Wilhelmina Hospital (CWZ)
RECRUITINGNijmegen, 6532SZ, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Leiden University Medical Center (LUMC)
RECRUITINGLeiden, ZA, 2333ZA, Netherlands
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Infirmary of Edinburgh
RECRUITINGEdinburgh, EH16 4SA, United Kingdom
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Skåne University Hospital
RECRUITINGMalmö, SE-20502, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tays Central Hospital
RECRUITINGTampere, Finland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital (UZ) Leuven
RECRUITINGLeuven, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital Southampton NHS Foundation Trust
RECRUITINGSouthampton, SO16 6YD, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospitals Birmingham NHS Foundation Trust
RECRUITINGBirmingham, B15 2GW, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••